Antiangiogenic Activity of Alofanib, an Allosteric Inhibitor of Fibroblast Growth Factor Receptor 2

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Fibroblast Growth Factor Receptor 2 (FGFR2) signaling is implicated in various cancers.
• Targeting FGFR2 is a potential therapeutic strategy in oncology.
• Allosteric inhibition offers a novel approach to modulate receptor activity.

Purpose of the Study:

• To investigate the anti-angiogenic effects of Alofanib, an allosteric inhibitor of FGFR2.
• To evaluate Alofanib's efficacy in preclinical cancer models.

Main Methods:

• In vitro assays assessing endothelial cell proliferation, migration, and vessel-like structure formation.
• In vivo studies using Matrigel implants and ovarian cancer xenografts in mice.
• Analysis of microvessel density in tumor tissues.

Main Results:

• Alofanib suppressed endothelial cell proliferation, migration, and in vitro angiogenesis.
• Alofanib significantly reduced microvessel density in Matrigel implants.
• Alofanib decreased the number of microvessels in SKOV-3 ovarian cancer xenografts.

Conclusions:

• Alofanib demonstrates potent anti-angiogenic activity both in vitro and in vivo.
• Alofanib's mechanism involves blocking FGFR2 extracellularly, inhibiting ligand binding.
• Alofanib shows promise as a therapeutic agent for inhibiting tumor angiogenesis in ovarian cancer.